References

  1. Bonvalot S, Vanel D, Terrier P, Le Pechoux C et al. Le Cesne, principes du traitement des sarcomes des tissus mous de l'adulte. EMC-Rhumatol-Orthopédie. 2004; vol 1(n° 6): 521- 541. PubMed | Google Scholar

  2. ESMO Clinical Practice Guidelines. Soft tissue and Visceral Sarcoma. Ann Oncol. 2014. PubMed | Google Scholar

  3. Derbel O, Cropet C, Meeus P, Gilly F-N, Vaz G, Thiesse P, Cellier D, Vince-Ranchere D, Blay J-Y, Ray-Coquard I. Adhesion to clinical practices guidelines (cpg's) and role on survival for soft tissue sarcoma patients: analysis of a population based cohort from Rhone-Alpes Region. Ann Oncol. 2012, Sept; 23 (Sup 9): xi 478-491. PubMed | Google Scholar

  4. Morère JF, Mornex F, Soulières D. Thérapeutique du Cancer -2eme édition. 2011.France. Springer-Verlag. Google Scholar

  5. Bui-Nguyen B, Italiano A, Delva F, Toulmond M. Chimiothérapie adjuvante des sarcomes des tissus mous de l'adulte. Bull Cancer. 2010 Jun;97(6): 673-677. PubMed | Google Scholar

  6. Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014 Dec;25(12):2425-32. PubMed | Google Scholar

  7. Ruiz-Soto Rodrigo, Auger Nathalie, Tournay Elodie, Gomez-Abuin Gonzalo, Terrier Philippe, Drusch Françoise, Domont Julien, Cioffi Angela, Boulet Bérénice, Blay Jean-Yves, Coindre Jean-Michel, Bénard Jean, Bonvalot Sylvie, Le Cesne Axel. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas. European Journal of Cancer. June 2011;Volume 47(Issue 9): Pages 1319-1327. PubMed | Google Scholar

  8. Italiano A, Toulmonde M, Bui-Nguyen B. Prise en charge des sarcomes des tissus mous avancés: quelle chimiothérapie après échappement aux anthracyclines? Bull Cancer. 2010 Jun;97(6): 679-686. PubMed | Google Scholar

  9. Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: a phase 2b randomized clinical trial. JAMA Oncol. 2015 Sep 17:1-9. PubMed | Google Scholar

  10. Patricia Pautier, Anne Floquet, Christine Chevreau, Nicolas Penel, Cécile Guillemet, Corinne Delcambre and al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. The Lancet Oncology. 2015 March; Vol 16( No4): p 457-464. PubMed | Google Scholar

  11. Penel N, Watelle F, Vanhuyse M, Adenis A.Traitement des sarcomes des tissus mous de l'adulte métastatiques: évolution actuelle des concepts. Bull Cancer. 2010 Jun;97(6): 687-691. PubMed | Google Scholar

  12. Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014 Oct 10;32(29):3299-306. PubMed | Google Scholar

  13. Demetri GD, Chawla SP, Van Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188-4196. PubMed | Google Scholar

  14. Federica Grosso, Robin Jones L, George Demetri D, Ian Judson R, Jean-Yves Blay, Axel Le Cesne et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8(7): 595-602. PubMed | Google Scholar

  15. Akira Kawai, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Tsukasa Yonemoto, Mitsuru Takahashi and others.Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. The Lancet Oncology. Mar 17, 2015; Vol 16 (No 4): p 406-416. PubMed | Google Scholar

  16. van der Graaf WT, Blay JY, Chawla SP et al. EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-1886. PubMed | Google Scholar

  17. Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013 Jul 1;31(19):2485-92. PubMed | Google Scholar

  18. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. EORTC Soft Tissue and Bone Sarcoma Group: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002 Mar;38(4):543-9. PubMed | Google Scholar

  19. Van Oosterom A, Verweij J. New drugs for the treatment of sarcoma. Hematol Oncol Clin North Am. 1995; 9(4):909-925. PubMed | Google Scholar